Non-Hodgkin Lymphoma (NHL) Market Insights Reveals Expected CAGR of 8%: Forecast -2023-7MM

Published on : May 03, 2017

Albany, New York, May 03, 2017: While most people are aware of the distressing effects of cancer, many are unfamiliar with specific forms of the disease like Non-Hodgkin disease (lymphoma). In recent years, awareness efforts by many different groups have helped shed light on this devastating form of cancer that affects the cells of the body's immune system. A new study, delivering the market insights of the disease has been recently added to the massive portfolio of Market Research Hub (MRH), and headlined as “Non-Hodgkin Lymphoma (NHL)- Market Insights, Epidemiology and Market Forecast -2023-7MM”. The main purpose of this study is to provide the global market overview and market size of the Non-Hodgkin Lymphoma for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan.

Non-Hodgkin Lymphoma (NHL) actually represents a group of different cancers and it is estimated to be the sixth most common cancer in the United States. It arises in lymphocytes present in lymph nodes of body parts such as neck, chest or under the arms. It widely spreads to the other lymph nodes and to other organs such as bone marrow, lungs, or liver. In the initial section, the report covers the type and stages of Non-Hodgkin Lymphoma along with risk factors, etiology, treatment etc. Depending on the stage and type of NHL, treatment can include chemotherapy, biological therapy, stem cell transplant, and/or radiation therapy. Due to its rising prevalence, research into the causes, prevention and treatment is being done in many medical centers throughout the world. In this study, the analysts have also included historical and forecasted epidemiological data for the diagnosed cases of Non-Hodgkin Lymphoma from 2012-2023.

According to the key findings of the report, the market size for Non-Hodgkin Lymphoma of 7 MM is expected to expand at a CAGR of 8% by 2023. The market of Non-Hodgkin’s lymphomas (NHL) is mainly driven by many promoting forces, such as, rising prevalence of Non-Hodgkin’s lymphomas (NHL) and other types of cancer, extensive R&D practices, rising concern of the population towards effects of Non-Hodgkin’s lymphomas (NHL) and rise in medical and healthcare expenses and infrastructure.

Moving further, the research examines the total number of cases in 7MM countries for the period 2016 to 2023. In the above-mentioned regions, based on diagnosed cases the report highlights the market growth for the present time. Also, to understand the future market competition in the 7MM market the report provides an insightful review of the key market drivers and barriers.

Click here to get more info with TOC in a PDF Format :

In the later part, an in-depth analysis of clinical trials including pipeline analysis and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL) are also mentioned. Additionally, marketed drugs such as Rituxan (MabThera) along with its efficacy, safety and side effects have been presented in details. At last, emerging therapies by the major players highlighted in the study are Copanlisib (Bayer AG), Pixantrone (CTI BioPharma Corp.) and Ibrutinib (Janssen Biotech, Inc).

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top